Patent Application
20220333184
The present invention relates to methods for amplifying at least one RNA, especially at least one mRNA contained in a sample, to the use of such method for preparing a full-length RNA library from a sample containing a plurality of RNA molecules, a method for sequencing the total RNA of specific cells or the whole exome of an organism and to methods for genetic diagnosis. Further, the invention relates to a kit containing reagents for performing at least one of the methods of the invention.
Despite all technological advancements in recent years, RNA sequencing, especially full-length mRNA sequencing or transcriptome or exome sequencing have remained a tremendous challenge. The exome includes all parts of the genome of an organism which are contained in the exons and which, after transcription of the genetic information and removal of introns via RNA splicing, result in mRNA which is translated into the final proteins of such organism. The transcriptome, on the other hand, includes all RNAs of one cell or a specific population of cells, especially all corresponding mRNAs.
Whole exome sequencing can tremendously contribute to the understanding of common as well as rare diseases. Mutations which affect or even eliminate the function of specific proteins are known to be the major cause of Mendelian diseases. E.g. Choi et al. (Proc Natl Acad Sci USA, 106 (45), p. 19096-19101 (2009)) and Bamshad et al. (Nat Rev. Genet., 12, 745-755 (2011)) reported on whole exome capture and massively parallel DNA sequencing for determining genetic variations which play a role in Mendelian and non-Mendelian diseases.
The transcriptome of especially cancer cells is of particular importance for a better understanding of carcinogenesis. However, also the analysis of molecular mechanisms and cellular pathways in other cell types like stem cells is a permanent focus of research, as is biomarker discovery for a variety of different applications and uses.
While the human and animal exomes and transcriptomes are of interest especially to advance treatment or prevention of diseases, for plant cells additional interest lies in a better understanding of plant genetics e.g. for improvement of crop plants by targeted mutation and genetic engineering.
The rapid analysis of genetic material requires easy to use, efficient and reliable tools. A major problem is the need to detect DNA or RNA of interest directly in small biological samples such as patient blood or other sources. These provide the various components of the genetic material only in minute amounts. In order to reach the required sensitivity, an amplification step is usually required in which the amount of the nucleic acids in a sample is increased prior to analysis. Alternatively, a detection method is applied in which the minute detection signal which is directly obtained from the DNA/RNA analyte is amplified.
Methods for the amplification of nucleic acids include PCR amplification and other nucleic acid amplification protocols. PCR amplification has the major advantage that within the pool of different DNA strands obtained from a biological material only the DNA sequence of interest is amplified. This is the basis for a reliable analysis of single genes in complex biological samples. In the last few years, the focus has shifted to next generation sequencing (NGS) techniques and RNA sequencing. Since there is no robust method to sequence RNA directly, all library preparation methods start by reverse transcription of the mRNA into DNA. The resulting single-stranded cDNA is then usually converted into a double-stranded DNA (dsDNA) during the so-called “second-strand synthesis”, which renders the oligonucleotides compatible with the sequencing machines. Moreover, adapter sequences are needed for the sequencing procedure. These adapters can only be introduced efficiently into dsDNA by tagmentation (transposase-mediated DNA fragmentation and primer addition) or via enzymatic ligation. This conversion process of single-stranded RNA into double-stranded DNA is the reason for the complexity of current RNA library preparation methods.
Recently, WO 2019/063803 disclosed a chemical ligation method which enables to chemically ligate single-stranded DNA with a similar efficiency as ligases show for dsDNA. The method uses the click chemistry concept which was independently defined by the groups of Sharpless and Meldal in 2001/2002 (Sharpless, K. B. et al., Angew. Chem. 2002, 114, 2708, Angew. Chem. Int. Ed. 2002, 41, 2596; Meldal, M. et al., J. Org. Chem. 2002, 67, 3057). The copper-catalyzed reaction of azides with alkynes to give 1,2,3-traizoles, which is a variation of the 1,3-dipolar Huisgen cycloaddition (R. Huisgen, 1,3,-Diploar Cycloaddition Chemistry (Ed.: A Padwa), Wiley, New York, 1984), has become the most widely used method to perform a click reaction. As a result of its mild conditions and high efficiency, this reaction has found a myriad of applications in biology and material sciences, such as e.g DNA labeling for various purposes (Gramlich, P. M. A. et al., Angew. Chem. Int. Ed. 2008, 47, 8350).
This chemical ligation principle has prompted various groups to develop library preparation methods without enzymatic ligation (Routh, A. et al., J. Mol. Biol. 427, 2610-2616 (2015), US 2018/0127816 A1 (Illumina, Inc.), Miura, F. et al., Nucleic Acids Research, Vol. 46, No. 16, e95 (2018)). Despite benefits in decreasing the number of protocol steps, e.g. by eliminating the need for a second strand synthesis or suppressing artefactual recombination and primer dimer formation, a slight decrease in sensitivity compared to conventional protocols was noted. Besides, due to the need to incorporate an artificial nucleotide during reverse transcription and as the resulting backbone mimic is not accepted by all polymerases employed in standard library preparation methods, broad commercial application of the new protocol is missing.
Accordingly, it was an object of the present invention to provide an improved concept for amplification of mRNAs and for preparation of full-length libraries especially of a plurality of mRNAs contained in a sample, e.g. a whole exome preparation or the total mRNA of a certain cell type of an individual. Facilitating sequencing or amplification of other RNAs, especially viral RNA, was another aspect of the research performed by the inventors. Furthermore, it was an object to provide a method which exploits the efficiency of the chemical ligation method for joining of single-stranded DNA, but which is compatible with standard enzymes in library workflows.
The present invention solves the above mentioned problem by providing an improved method for amplifying and/or sequencing RNA, preferably mRNA, especially for preparation of a full length mRNA library for the total mRNA of certain cells or for the whole exome of an organism.
In a first aspect the invention relates to a method for amplifying and or sequencing at least one RNA, preferably mRNA, contained in a sample, the method comprising:
In a third aspect, the invention relates to the use of such inventive methods for preparing a full-length mRNA library from a sample containing a plurality of mRNA molecules.
In a fourth aspect, the invention is directed to a method for sequencing the total mRNA of one or more types of cells of an organism or the whole exome of an organism, the method comprising providing a sample containing such exome or total cell mRNA, preparing a library of full-length mRNA by performing the method according to the invention as described herein and determining the sequence of the obtained total cell mRNA or exome.
The amplification of full-length RNA from natural sources, especially of full-length mRNA, the total mRNA of specific cells or cell types, or even the whole exome of an organism, i.e. the complete coding regions of protein encoding genes, via commonly used methods is still a complicated and time-consuming procedure. The present invention employs so-called “click chemistry” to facilitate amplification of a full-length RNA, and even the amplification of several or a multitude of RNAs contained in a sample can be performed in one single procedure. Determination of the sequence of the RNAs can be performed either after amplification or even during second strand synthesis of cDNA(s) obtained by reverse transcription of the RNA(s).
In principle, the method of the invention can be applied to all kinds of RNA, if amplification and/or sequencing of such RNA and especially of a mixture containing any kind of RNA is desired. The application of the inventive method to mRNA is preferred, and another preferred RNA to be included by such method is viral RNA in any form, i.e. also a viral RNA which is integrated into the genome of a host. While the following detailed exemplary description of the inventive method often refers primarily to mRNA, it is to be understood that the same measures and steps can also be performed in order to amplify or sequence viral RNA or other RNAs in the same manner.
In the overall context of the present invention, mRNA refers to messenger RNA, i.e. a ribonucleic acid which is encoded by the DNA contained in a cell or organism and which can be translated into a protein by cellular mechanisms. Additionally, as defined here, the terms RNA and mRNA can also encompass synthetic ribonucleic acids or mRNAs which include modified nucleotides. An RNA or mRNA is further meant to include nucleic acids which contain analogues of the sugar moiety. While natural RNAs and mRNAs contain one or more bases selected from the group consisting of adenine, uracil, cytosine or guanine, non-native bases can also be included.
The methods of the present invention can be applied to a sample which contains only one kind of RNA or mRNA. That means that the sample contains only nucleic acids having the same nucleotide sequence and the same number of nucleotides. In other embodiments of the invention, the sample can contain two or more different RNAs and/or mRNAs, preferably two or more different mRNAs. In the context of the present invention, the term “different RNAs and/or mRNAs” is intended to include not only nucleic acids having different nucleotide sequences but also RNAs and/or mRNAs which have the same nucleotide sequence but, due to whatever reasons, contain a different number of nucleotides.
The terms “click chemistry” or “click-reaction” or the like as used within the context of the present invention are intended to refer to all corresponding methods described in the art and the exemplary publications mentioned in the above “Background of the Invention” section. It is especially referred to WO 2019/063803 A1, the disclosure of which is specifically included for the purposes of the present invention, especially as far as it relates to conditions, reagents and methods to perform click reactions. Preferably, in the context of step f), a copper catalyzed azide-alkyne cycloaddition reaction (CuAAC) is performed and most preferably under conditions as described in WO 2019/063803 A1. Within the context of the invention it is, however, also possible and preferred to perform a strain-promoted copper-free click ligation (SPAAC) which is a further well-known method for ligating alkyne- and azide-modified nucleic acids (e.g. I. S. Marks et al., Bioconjug Chem. 2011 22(7):1259-1264; M. Shelbourne et al., Chem. Commun. 2012, 48, 11184-11186; M. Shelbourne et al., Chem. Commun. 2011, 47, 6257-6259). Suitable alkyne and azide residues for modification of nucleotides and nucleic acids for use in the click reactions have been described in the prior art and are well-known to the skilled person. Examples of click-ready 5′-alkyne- or azide modified oligonucleotides are also outlined in
Shortly summarized, the first aspect of the invention includes cDNA preparation from the one or more (m)RNA templates via reverse transcription, during or after which the obtained one or more cDNAs are modified at their 3′-end to include an alkyne- or an azide-modification. More specifically, one partner of a pair of molecules which participate in a click reaction is attached to the cDNA(s). Subsequently, an adapter comprising a poly- or oligonucleotide sequence and, at its 3′-end, the second partner of the pair of molecules, is ligated via click reaction to the cDNA(s). Use of this adapter and a specific second primer allow for a highly effective amplification of the cDNA(s) or for a direct sequencing of the cDNA(s).
This first inventive method includes an initial step a), in which a first primer which is complementary to a sequence which is located at or near the 3′-end of the at least one (m)RNA, is added to the sample containing (m)RNA(s). Addition of this first primer to the sample occurs under conditions which allow for hybridization of the first primer to the complementary (m)RNA sequence.
The at least one first primer includes a sufficient number of nucleic acids which are complementary to the respective target (m)RNA to allow for an effective hybridization of the primer to the (m)RNA. The first primer can include any number of nucleotides which is considered useful in DNA/RNA amplification procedures. In a preferred embodiment, the first primer consists of at least 5 nucleotides, preferably at least 10 or at least 15 nucleotides. In such preferred embodiments, the first primer further consists of up to 60 nucleotides, preferably up to 50 nucleotides and most preferably of up to 45 nucleotides. Conditions to effect or favor hybridization of the at least one first primer to the at least one mRNA are well known to the skilled person and include those as described e.g. in J. Zhang et al., Biochem. J., 1999, 337, 231-241. Especially favorable conditions can also easily be determined by the skilled person by preliminary tests.
In a second step b) of this first inventive method, starting from the 3′-end of the primer hybridized to the at least one (m)RNA, the (m)RNA is reverse-transcribed under conditions including addition of a reverse transcriptase and nucleotides to the sample to provide full-length cDNA(s) of the at least one mRNA. While the naturally occurring 4 types of nucleotides dATP, dCTP, dGTP and dTTP are usually employed in the context of the present invention, also artificial nucleotides can be included as long as they do not impair the cDNA formation of any further steps of the method of this invention. As for step a), conditions for the reverse transcription are also well known to the skilled persons.
In an intermediate step c), at least excess nucleotides used in step b) are removed. In preferred embodiments of the invention, also remaining (m)RNA(s), excess reverse transcriptase and excess first primer(s) can be removed during this step. In an especially preferred embodiment, a cDNA purification is performed according to methods known in the art and the purified cDNA included in the further steps of the method.
In the following step d), a dideoxy nucleotide (ddNTP), which is modified at the 3′-position to include a first partner of an azide/alkyne click-reaction pair, and a template-independent polymerase is added to the sample. The term “dideoxy nucleotide” or ddNTP stands for nucleotides which do not have 2′- nor 3′-hydroxyl groups. Within the context of the present invention, the ddNTPs include one of the bases adenine, thymine, cytosine or guanine. The modified dideoxy nucleotide is added to the cDNA sequence at its 3′-end by the polymerase and, since the dideoxy nucleotide does not contain the required 3′-hydroxyl group, no further chain extension can occur and the attached azide or alkyne group is available for a reaction of the 3′-end of the cDNA with a second click-reaction partner. In a preferred embodiment of the invention, the alkyne or azide group is attached to the 3′-position of the deoxyribose moiety of the ddNTP and also preferably, the ddNTP contains an azide group attached to the molecule.
In a further intermediate step e), at least an excess of the modified dideoxy nucleotide used in step d) is removed. In preferred embodiments of the invention, also during this step eventually remaining (m)RNA(s), excess reverse transcriptase and excess first primer(s) can be removed and/or the template-independent polymerase as used in step d).
In step f), an adapter molecule is added as the second click-reaction partner to the sample. The adapter molecule comprises an oligo- or polynucleotide sequence and contains attached to its 5′-end the second partner of the pair of azide and alkyne molecules. A click-reaction which occurs between the alkyne- and the azide groups ligates the adapter molecule to the 3′-end of the cDNA under formation of a triazole linkage. The adapter molecule serves for binding of a second primer in the next step of the inventive method via hybridization and subsequent amplification. Accordingly, the adapter molecule contains a number of nucleotides which is sufficient to allow for binding of such second primer, usually at least 6 nucleotides, preferably at least 10 and more preferably at least 15 nucleotides. In a preferred embodiment, the adapter molecule contains a maximum of 100 nucleotides, more preferable a maximum of 80 or 60 nucleotides. Furthermore, it is also considered a preferred embodiment of the invention to use an adapter molecule in step e, which contains an alkyne attached to its 5′-end.
In the next step g), the above mentioned second primer is added which comprises a nucleotide sequence, which is complementary to all or part of the adapter molecule. The nucleotide sequence of the second primer is complementary to at least 6 nucleotides at the 5′-end of the nucleotide sequence of the adapter molecule and it contains at its 3′-end a nucleotide which is complementary to the dideoxy nucleotide at the 3′-end of the cDNA(s). Accordingly, the second primer hybridizes and binds to the ligated adapter/cDNA molecule at a position which overlaps the triazole linkage which was formed via click reaction.
In the further steps, the second primer is extended by addition of a DNA polymerase. As far as an amplification of the one or more RNAs is desired, one or more third primers can be added which are identical to at least a part of the first primer(s), and the obtained cDNAs then can be amplified according to known methods. This option is defined by steps h) and j). The third primer can e.g. comprise less nucleotides than the first primer but still ensure hybridization. The third primer can also include a specific sequence which ensures hybridization and further sequences which are not complementary to the target sequence of the first primer on the at least one mRNA.
As far as sequencing of the one or more RNAs is desired, there are different options within the context of the present invention. Firstly, after step g), a DNA polymerase can be added to achieve chain extension of the second primer to produce “full length” second strand DNA(s) including sequences which are complementary to the whole cDNA(s) produced in step b). These second strand DNA(s) can be sequenced without being amplified according to known methods for single molecule sequencing (system and kits available e.g. from Pacific Biosciences, https://www.pacb.com/). This option is defined in steps h) and i).
In an alternative embodiment, the sequencing can be performed simultaneously with chain extension of the second primer after adding a DNA polymerase. This alternative option is defined by step h′). The sequencing can e.g. be performed according to the well known Sanger sequencing method or methods developed based on this principle, or a sequencing-by-synthesis method (systems and kits e.g. available from Illumina, https://illumina.com/).
The method of the present invention for the first time allows to produce amplified cDNA for a specific RNA sample without the need for fragmentation of the RNA and random priming as was required by commonly used processes, one of which is schematically represented in
As the first primers, various different alternatives and respective polynucleotides can be considered within the context of the invention. Firstly, random primers can be used as known from prior art methods. For this first alternative, rather short nucleotide sequences having a random sequence which hybridizes to random parts within the RNA or RNAs, preferably mRNA or mRNAs, can be employed. The products of a process using such random first primers have different lengths.
In a second alternative and a preferred embodiment of the invention, specific primers are used instead of random primers. This alternative is especially applicable in cases where the sequence or identity of at least one RNA contained in the sample is known. In cases where a sample is analyzed for the presence of one or more known (m)RNAs which could be present in the sample, corresponding specific primers can be used and allow for the detection of such known (m)RNAs.
In a further alternative which is also a preferred embodiment of the invention, a poly(dT) primer is used as the at least one first primer for mRNA amplification. A poly(dT) primer usually comprises 6 to 30 dT nucleotides. The primer is added to the sample under conditions which allow for hybridization to the poly(A) tail(s) of the at least one mRNA in the sample. All mRNA molecules contain a poly(A) tail at their 3′-end which consists of multiple adenosine monophosphates. The poly(A) tail is added to eukaryotic RNA via polyadenylation which takes place after the transcription of the gene is concluded. The poly(A) tail however does not have a coding function during translation. Thus, the poly(A) tail is an ideal target for primer hybridization and providing a corresponding poly(dT) primer does not require any knowledge about the sequence of the target mRNA. Furthermore, use of the poly(dT) primer allows for reverse transcription and amplification of the complete coding sequence of the mRNA(s) contained in a sample.
In certain embodiments, the invention also includes the use of different kinds of primers, i.e. random and specific primers or random and poly(dT) primer or specific and poly(dT) primers. This is especially useful in cases where primers also include a specific anchor or capture sequence. For instance, a specific primer can be included for detecting the presence of a known mRNA in a sample. The presence e.g. of a capture sequence attached to the 5′-end of such specific primer provides the option to, in a later step after amplification, attach the amplified cDNA obtained for this known mRNA to a solid support, to separate the cDNA attached to the solid support from other amplification products and to detect the presence of such cDNA. Other useful options provided by the inclusion of capture or anchor sequences attached to the first primer(s) are easily recognizable by the skilled person and are also encompassed within the context of the present invention.
In an especially preferred embodiment of the invention for mRNA amplification, a poly(dT) primer is used as the at least one first primer, which includes an anchor sequence. This anchor sequence provides an additional 5′-end-extension of usually 2 to 50 nucleotides. Preferably the anchor sequence contains at least 5 and more preferably at least 8 nucleotides. In further preferred embodiments, the anchor sequence contains a maximum of 40, more preferably a maximum of 30 nucleotides. This presence of such anchor sequence e.g. provides a possibility to ensure uniform positioning of the poly(dT) primer(s) used in the inventive method.
In a further preferred embodiment, 3′-alkyne- or 3′-azide-modified ddGTP or 3′-alkyne- or 3′-azide-modified ddCTP is added in step d) of the inventive method. It has been observed that the presence of one of the bases G or C at the 3′-end of the cDNA results in an especially efficient hybridization and attachment of the second primer in the following step g). The best binding results were obtained where the 3′-end of the cDNA is modified to include G by adding a 3′-alkyne- or 3′-azide modified ddGTP to the cDNA in step d), the most preferred modified dideoxy nucleotide being 3′-azido-2′,3′-dideoxy GTP (AzddGTP).
In correspondence with the above mentioned preferred embodiments for step d), it is further preferred that the second primer in step g) contains at its 3′-end dG or dC, most preferably dC. The method of the present invention requires the second primer to contain at its 3′-end a nucleotide which is complementary to the nucleotide at the 3′-end of the cDNA(s). Accordingly, in the preferred embodiment, in which an alkyne- or azide-modified ddGTP is used in step d), the second primer contains dC at its 3′-end. In the other preferred embodiment, in which alkyne- or azide-modified ddCTP is included in step d), the second primer correspondingly contains dG at 3′-end. In line with the above disclosed most preferred embodiment using the modified ddGTP above, in such most preferred embodiment a second primer is used which contains dC at its 3′-end. In a further preferred embodiment of the present invention, the second primer includes a dC at the second position of its 3′ end. It has been realized by the inventors that the presence of dC at this position where the second primer overlaps the triazole linkage formed by the click reaction, improves primer binding and subsequent primer extension considerably.
As the template independent polymerase in step d) preferably the enzyme terminal deoxynucleotidyl transferase (TdT) is used. The enzyme is a member of the X family of DNA polymerases and catalyzes the addition of nucleotides to the 3′-terminus of DNA molecules. Unlike most other DNA polymerases, TdT does not require a template. It can add nucleotides to a 3′-overhang as a preferred substrate, however, also works well in adding nucleotides to blunt or recessed 3′-ends. Accordingly, it has found important and wide spread application in molecular biology, i.e. in rapid amplification of cDNA ends (RACE), PCR and more recent enzymatic de novo gene synthesis.
In the context of the present invention, it is an option and also a preferred embodiment to include at least one of the primers and the adaptor molecules which include a moiety which comprises a detectable label or tag, or which allows for immobilization on a solid support. One of such options has already been described above for the first primer(s). Such moiety can for example be able to form a covalent bond to a solid support directly or indirectly via further molecules. For example in cases in which it is intended to capture amplified nucleic acids for further detection or sequencing, immobilization to a solid support can be highly advantageous and is commonly used in automated sequencing methods. In line with such embodiment, one of the primers or the adaptor used in the present invention can also be present already attached to a solid support and the method be performed in the presence of such solid support. As a solid support, any material can be included or added directly or at a later stage which enables capturing and also separation of the attached molecules from the reaction mixture. As solid support, a variety of materials and molecules can be included and used within the context of the present invention. E.g., flat or three-dimensional surfaces can be provided as a solid support, e.g., beads to which a primer or adaptor is attached or can be attached via subsequent binding reaction, can be used advantageously in this context. Furthermore, it is also possible to use one of the primers or the adaptor in a labelled form, i.e. including a detectable label or tag to allow for the detection of amplification products. Especially in cases, where specific primers are used, a corresponding detection of the presence of the amplified cDNAs is easy to be carried out by methods known to the skilled person.
Also, the above outlined options can be combined to provide for capture and detection of the amplified cDNAs. In an especially preferred further embodiment of the invention, at least one of the primers or adaptor used in the method of the invention is attached to a solid support or is connected or bound to a molecule which facilitates binding to a solid support, and at least one other of the primers and adaptor molecules contains a detectable label or a molecule via which a detectable label can be attached. These embodiments of the invention allow for a simple and preferably also automated detection of amplification products and, thus, the presence of a specific mRNA in the sample to be analyzed.
While the above described preferred examples cannot exhaustively list all possible variations and benefits of the inventive method, the skilled person can easily adapt the method to best suit the specific purpose of research or diagnosis. Especially combinations of the method of the invention with further known procedures are therefore included within the scope of the present invention.
A variation of the method of the invention and a second aspect of the present invention is shown in
In the context of the method of the invention and the above described second aspect of the invention, instead of performing an amplification via steps h), it is also possible to directly perform sequencing according to known methods in step h′). E.g. a Sanger sequencing can be performed directly using the product obtained in step g) of the inventive method or the circular DNA/primer construct as shown at the bottom of
A further subject and third aspect of the present invention is the use of the above described inventive methods for amplifying of one or more mRNAs contained in a sample for preparing a full length mRNA library. Especially in the context of the preferred embodiment of the invention, in which a poly(dT) primer is used as the at least one first primer, the method allows for amplification of the complete mRNA sequences contained in the sample. This is especially useful, when the sample contains the total mRNA of one or more types of cells of an organism or even the whole exome of an organism, that is the total mRNA which will be translated into protein in a specific cell or an organism.
A further, fourth subject of the present invention relates to the methods and use of the invention as detailed above and further including the determination of the sequence of an amplified mRNA or obtained mRNA library. Such method allows for a reliable sequencing of the total mRNA of cells of an organism and even the whole exome of an organism and ensures detection also of rare transcripts within the mRNA pools. Providing such method is especially useful in medical research and clinical diagnostics, e.g., for variant mapping in complex disorders, investigation of genetic aberrations, determining the genetic basis for a disease or for diagnosing Mendilian disorders and other uses.
Further fifth and sixth subjects of the present invention provide kits for performing at least one of the above-mentioned methods and uses of the invention.
A kit allowing for amplifying and/or sequencing at least one (m)RNA contained in the sample according to the first aspect of the invention comprises
Furthermore, in preferred embodiments of the present invention, the kits of the invention can contain further useful reagents for performing the inventive methods, especially at least one of
The reagents contained in the kits for performing such methods can easily be adapted by the skilled person to include additional reagents or to set aside reagents which are not required for specific methods.
All information disclosed above with regard to one subject of the present invention is considered to equally apply in the context of other subjects for which this information, even if not explicitly repeated, has recognizable relevance within the context of the invention.
The following Examples further illustrate the invention:
For internal control, next to house-keeping genes like GAPDH, mRNAs (0.1 μg) of eGFP (Baseclick), CleanCap®Cas9 (Trilink), CleanCap®β-Gal (Trilink) and CleanCap®Fluc (Trilink) were spiked into 2 μg of Jurkat cell total RNA pool. To this RNA pool, 1 μL dNTP mix (10 mM) and 2 μL of the Poly(dT) Primer (100 μM) were combined to a total volume of 13 μL with RNase free H2O. The mixture was incubated at 65° C. for 5 min and cooled down to 0° C. for 3 min to allow hybridization. For cDNA synthesis 4 μL 5×SuperScriptIV Buffer, 1 μL dithiothreitol (100 mM), 200 units of Superscript IV reverse transciptase were added and filled up with RNase free water to a total volume of 20 μL. The mixture was incubated at 50° C. for 20 min, at 80° C. for 10 min and cooled down to 4° C. for 3 min. After cDNA synthesis 3 μL 10×RNase H Buffer, 1 μL RNase A (10 mg/mL), 1.4 μL RNase H (5 U/μL) and 4 μL shrimp alkaline phosphatase (1 U/μL) and 0.6 μL dH2O were added to remove RNA and excess of nucleotides. The mixture was incubated at 37 C for 25 min, at 65 C for 15 min and cooled down to 0 C for 3 min and then cleaned by a spin column method (BaseClean Kit) according to manufacturers' instruction for PCR products and eluted with 17 μL dH2O.
The purified mixture was directly used for azide elongation with 3′-N3-ddGTP. To 17 μL purified cDNA mixture 5 μL 5×TdT Buffer, 1 μL 3′-N3-ddGTP (10 mM) and 2 μL of terminal deoxynucleotidyl transferase (20 U/μL) was added. The solution was incubated at 37° C. for 1 h and cooled down to 0 C for 3 min. Modified cDNA was purified by a spin column method (BaseClean Kit) according to manufacturers' instruction for PCR products and eluted with 9 μL.
Click ligation was performed using 9 μL of the purified and azide-modified cDNA, 0.5 μL of Alkyne Adapter (100 μM), 2.5 μL Activator240 (baseclick GmbH), 0.5 μL dH2O and two reactor pellets. The reaction mixture was incubated at 45 C, 600 rpm, for 40 min. After the reaction, the supernatant was transferred to a new vial. The pellets were washed with 12.5 μL water and the supernatant was transferred to the supernatant before. The click ligated cDNA was cleaned using a spin column method (BaseClean Kit) according to manufacturers' instruction for PCR products and eluted with 10 μL.
After click ligation, the cDNA pool was amplified using untargeted primer (Adapter Primer1 and Poly(dT) Primer Reverse) to obtain a full-length mRNA library. In a 200 μL reaction vial 11.5 μL dH2O, 4 μL 5×OneTaq Buffer, 1 μL Adapter Primer1 (10 μM), 1 μL Poly(dT) Primer Reverse (10 μM), 0.4 μL dNTP Mix (10 mM), 2 μL of the purified click ligation mixture and 0.13 μL OneTaq DNA Polymerase (5000 U/μL) (New England Biolabs) were combined. The sample was subjected to a thermal cycling program in a thermocycler (B
As a standard cycling following conditions were used with different extension times (step 4):
The PCR mixture was cleaned using a spin column method (BaseClean Kit) according to manufacturers' instruction for PCR products and eluted with 10 μL dH2O. In
For bioanalyzer measurements as shown in
Oligonucleotides:
Modifications:
After click ligation (procedure described in example 3), specific genes were amplified from the cDNA pool using targeted primer (various Intern Primer Reverse and Forward, see table below), which result in specific PCR fragments. In a 200 μL reaction vial 11.5 μL dH2O, 4 μL 5×OneTaq standard reaction buffer, 1 μL Intern Reverse Primer (10 μM), 1 μL Intern Forward Primer (10 μM), 0.4 μL dNTP mix (10 mM), 2 μL of the purified and click ligated cDNA mixture and 0.13 μL OneTaq DNA Polymerase (5000 U/μL) (New England Biolabs) were combined. The sample was subjected to a thermal cycling program in a thermocycler (B
5 μL unpurified aliquots of each PCR amplification were analyzed on 1.5% agarose gels (10×15 cm) prepared in TAE buffer (20 mM TRIS, 10 mM acetic acid, 0.5 mM EDTA).
Oligonucleotides:
After click ligation (procedure described in example in
5 μL unpurified aliquots of each PCR amplification were analyzed on 1.5% agarose gels (10×15 cm) prepared in TAE buffer (20 mM TRIS, 10 mM acetic acid, 0.5 mM EDTA).
For Sanger sequencing as shown in
Oligonucleotides:
The feasibility of the triazole readover was exemplified for reverse transcription of a Model RNA sequence. The RNA was hybridized to Primer1 and then reverse transcribed in the presence of 200 μM dTTP, dGTP, dCTP and 3′-azido-ddATP using MuLV reverse transcriptase. Nucleotides and enzyme were removed by purification of the cDNA using the nucleotide removal kit (Q
Alkyne Oligo1 was clicked to the purified cDNA in a 200 μL reaction vial with a single reactor pellet (600-800 μm, containing elemental copper) in a total 12.5 μL reaction mix and incubated at 45 C for 60 min. The reaction mix consisted of 800 μM THPTA, 20 mM MgCl2, 5% DMSO, 7 μM of Alkyne Oligo1 and about 4 μM purified cDNA. dH2O was used to adjust the volume to a final 12.5 μL if necessary.
After the incubation the sample was briefly spinned down and the supernatant was transferred to a new vial to stop the reaction. The crude click reaction was diluted 1:1000, 1:5000 and 1:10000 (max. 4 nM, 0.8 nM and 0.4 nM) for PCR amplification without further purification.
In a 200 μL reaction vial, PCR amplifications were prepared in a total volume of 20 μL. Click reaction dilutions were combined with 200 μM dNTPs, 10 pmol of Primer2 and Primer3 and 1 U polymerase. For the various polymerases, Pfu, Phusion, Q5, One Taq and Dream Taq buffers were used according to manufacturers' recommendations. The samples were subjected to a thermal cycling program in a thermocycler (B
As a standard cycling condition following conditions were used:
For the Pfu polymerase different template dilutions and an alternative cycling condition were studied:
After the incubation the sample was briefly spinned down and an aliquot was analyzed on 3% agarose gels (10×15 cm) prepared in TAE buffer (20 mM TRIS, 10 mM acetic acid, 0.5 mM EDTA).
Samples were prepared with 20% purple loading dye (NEB), and low molecular weight DNA ladder (25-766 bp, NEB, N3233) was prepared accordingly; usually 0.5 μL marker were used in 5 μL loading volume. Gels were run in TAE buffer applying constant power (10 W, max. 500 V, max. 100 mA) for 60 min. Then, gels were incubated in a freshly prepared 1:10000 ethidium bromide dilution for 15 min and then destained in dH2O for 15 min. For visualization a Gel Doc EZ Imager (B
Oligonucleotides:
Resulting cDNA after reverse transcription:
Resulting click product:
AT = A and T joined via backbone mimic
Resulting PCR product:
Modifications:
In a final volume of 25 μL the samples contained 1 μM Oligo2, 1 mM 3′-Azido-2′,3′-dideoxyguanosine-5′-triphosphate or 3′-Azido-2′,3′-dideoxyuridine and TdT-enzyme (2 U/μl) in 1×terminal nucleotidyl transferase buffer (25 mM Tris-HCl (pH 7.2), 200 mM potassium cacodylate, 0.01% (v/v) Triton X-100, 1 mM CoCl2) for TdT-reactions. The reactions were incubated overnight (12-15 h) at 37 C and stopped by heating to 70 C for 10 min. The mixture was purified using the QIAquick Nucleotide Removal Kit and eluted in 30 μL water.
In a 200 μL reaction vial two reactor pellets (600-800 μm, containing elemental copper) were combined with 12.5 μL reaction mix and incubated at 45 C for 60 min. The click reaction mixture consisted of 800 μM THPTA, 40 mM MgCl2, 5% (v/v) DMSO in H2O, 1 μM of Alkyne-Oligo3 and about 0.3 μM purified azide oligonucleotide from TdT reaction. As a reference a reaction mixture consisted of 800 μM THPTA, 40 mM MgCl2, 5% (v/v) DMSO in H2O, 1 μM of Alkyne-Oligo3 and about 1 μM of Azide-Oligo2 was mixed.
After the incubation the sample was briefly spinned down and the supernatant was transferred to a new vial to stop the reaction. Samples were analyzed on a 20% polyacrylamide gel. As a reference low molecular weight DNA ladder (25-766 bp, NEB, N3233) was used.
For denaturing PAGE of oligonucleotides, samples were mixed with urea (50 v/v) and loaded on 20% denaturing polyacrylamide gels (7.5 mL Rotiphorese® Sequencing gel concentrate 750 μL Rotiphorese® Sequencing buffer concentrate, 2.09 mL bidistilled water, 3 mL 6 M urea solution, 1.5 mL 10×Tris-borate-EDTA (TBE) buffer (1 M tris, 1 M H3BO3, 25 mM EDTA), 150 μL ammonium persulfate (10% (w/v), 10 μL tetramethyl ethylene diamine (W×D×H=7.5×0.1×8.3 cm). Gel electrophoreses were performed in 0.5×TBE buffer at 150 V for 2 h. The gel was stained in ethidium bromide solution and washed with water. Afterwards the bands were visualized using Gel Doc™ EZ System by BioRad and analyzed using Image Lab™ software.
Oligonucleotides:
Modifications:
| Number | Date | Country | Kind |
|---|---|---|---|
| 19219326.6 | Dec 2019 | EP | regional |
| 20158810.0 | Feb 2020 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/087393 | 12/21/2020 | WO |
